| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K88742110 | CTRPv2 | pan-cancer | AAC | -0.023 | 0.6 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | 0.1 | 0.6 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.028 | 0.6 |
| mRNA | MS-275 | GDSC1000 | pan-cancer | AAC | 0.031 | 0.6 |
| mRNA | BRD-K01737880 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.6 |
| mRNA | BEC | CTRPv2 | pan-cancer | AAC | 0.043 | 0.6 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.025 | 0.6 |